Pharmaceutical Manufacturing of Sodium Chloride Nasal Solution

The contract pertains to the manufacture of a sterile 0.65% sodium chloride nasal solution in 50 mL containers, with all production must adhere to FDA regulations, current Good Manufacturing Practices, and USP <797> standards for sterile compounding. The product is intended for nasal use and must meet stringent purity, sterility, and stability requirements to ensure patient safety and regulatory compliance. Production must occur within a controlled environment that prevents microbial contamination and ensures consistent product quality throughout the manufacturing process. The contract is classified as a subcontract under NAICS code 325412, issued by the Department of Defense through the Medical Supply Chain Pharm FSA, with performance to take place at JBPHH, 96853-5256. The solicitation was posted on July 16, 2026, and responses are due by July 22, 2026, indicating a tightly structured timeline for proposals. The procurement is part of a broader defense supply initiative requiring reliable, high-quality pharmaceutical products for military and federal healthcare systems, demanding full traceability, documentation, and adherence to federal pharmaceutical standards without deviation.